Inventiva Pharma Company Profile
Background
Inventiva Pharma is a clinical-stage biopharmaceutical company headquartered in Daix, France, specializing in the development of oral small molecule therapies for diseases with significant unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company's mission is to develop novel and differentiated therapies to improve patient outcomes in these therapeutic areas. Inventiva's vision is to become a leader in the development of innovative treatments targeting nuclear receptors, transcription factors, and epigenetic modulators. The company is publicly listed on Euronext Paris (ticker: IVA) and the Nasdaq Global Market in the United States (ticker: IVA).
Key Strategic Focus
Inventiva's strategic focus centers on advancing its pipeline of oral small molecule therapies targeting diseases with substantial unmet medical needs. The company's core objectives include:
- Developing Lanifibranor: A novel pan-PPAR agonist currently in a pivotal Phase III clinical trial (NATiV3) for the treatment of non-alcoholic steatohepatitis (NASH).
- Advancing Odiparcil: A drug candidate for the treatment of mucopolysaccharidosis type VI (MPS VI), a rare genetic disorder.
- Exploring Oncology Programs: Developing a portfolio of early research projects in oncology, focusing on the Hippo signaling pathway.
The company utilizes proprietary technologies and scientific methodologies, including an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, and a wholly-owned research and development facility.
Financials and Funding
In October 2024, Inventiva completed a significant financing round, raising €348 million primarily from American venture capitalists, with participation from Sofinnova and Andera Partners. This funding is intended to support the ongoing Phase III clinical trial of lanifibranor for NASH.
Pipeline Development
- Lanifibranor: Currently in the NATiV3 Phase III clinical trial for NASH, with results expected in 2026.
- Odiparcil: Development suspended as the company reviews available options for its further development.
- Oncology Programs: Early research projects focusing on the Hippo signaling pathway are in progress.
Technological Platform and Innovation
Inventiva's technological platform includes:
- Proprietary Technologies: An extensive library of approximately 240,000 pharmacologically relevant molecules, with about 60% being proprietary.
- Scientific Methods: Expertise in developing compounds targeting nuclear receptors, transcription factors, and epigenetic modulators.
Leadership Team
- Frédéric Cren: Chairman and CEO, co-founder of Inventiva.
- Andrew Obenshain: Chief Executive Officer.
- Jean Volatier: Chief Financial Officer.
- Alice Roudot-Ketelers: Chief Operating Officer.
- Martine Zimmermann: Executive Vice President of Regulatory Affairs and Quality Assurance.
- Pascaline Clerc: Executive Vice President of Strategy and Corporate Affairs.
- Jason A. Campagna: President of Research and Development and Chief Medical Officer.
Market Insights and Competitor Profile
The market for NASH treatments is expanding, driven by increasing disease prevalence and limited approved therapies. Inventiva competes with companies including Madrigal Pharmaceuticals, BioMarin Pharmaceutical, and Ipsen.
- Madrigal Pharmaceuticals: Focuses on NASH treatments with an approved drug in the U.S.
- BioMarin Pharmaceutical: Specializes in rare genetic diseases.
- Ipsen: A global biopharmaceutical company with focus on oncology and rare diseases.
Inventiva faces a competitive environment where some rivals have approved products and established commercial infrastructures, placing Inventiva at a relative disadvantage as a clinical-stage company without commercial operations.
Strategic Collaborations and Partnerships
Inventiva has established key partnerships to enhance development and commercialization capabilities:
- Sino Biopharm: To develop and commercialize lanifibranor in Greater China.
- Hepalys Pharma, Inc.: To develop and commercialize lanifibranor in Japan and South Korea.
Operational Insights
Inventiva leverages proprietary technologies and strategic partnerships as competitive advantages. The company's wholly-owned R&D facility supports its scientific endeavors, especially in targeting nuclear receptors, transcription factors, and epigenetic modulators.
Strategic Opportunities and Future Directions
Inventiva's strategic roadmap includes:
- Completing the Phase III clinical trial for lanifibranor in NASH with results anticipated in 2026 and pursuing subsequent regulatory approvals.
- Exploring additional therapeutic indications for lanifibranor and advancing oncology research programs centered on the Hippo signaling pathway.
- Strengthening and expanding partnerships to optimize development and future commercialization potential.
Contact Information
- Official Website: Inventiva Pharma
- Social Media:
- Twitter: @InventivaPharma
- LinkedIn: Inventiva Pharma
